Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05042258 | RECRUITING | Atopic Dermatitis

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Sponsor:

Northwestern University

Information provided by (Responsible Party):

Amy Paller

Brief Summary:

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Condition or disease

Atopic Dermatitis

Sleep Disturbance

Intervention/treatment

Dupilumab

Phase

PHASE4

Detailed Description:

Subjects will complete two overnight sleep studies, before and after using dupilumab for 12 weeks, to assess the effect of dupilumab on sleep disturbance in eczema patients. These overnight visits will include PSG, blood draws, skin sensors, urine collection, tape stripping, and photography. Subjects will be given dupilumab to use for 12 weeks at home before returning for the second sleep study.

Study Type : INTERVENTIONAL
Estimated Enrollment : 40 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Actual Study Start Date : 2024-08-12
Estimated Primary Completion Date : 2025-06
Estimated Study Completion Date : 2025-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 6 Years to 17 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Participants, 6-17 years old at time of enrollment.
  • * Moderate to severe chronic AD inadequately controlled by topical treatment, diagnosed according to Hanifin and Rajka criteria by a pediatric dermatologist or allergist.
  • * AD severity will be determined at baseline with Validated Investigator Global Assessment (vIGA) score of moderate (3) or severe (4).
  • * Patient assessed or parent-proxy (under 8 years old) PROMIS sleep disturbance T-score ≥60.
  • * Willing and able to comply with visits and study-related procedures.
  • * On stable regimens (consistent use 14 days before Day 1 of study enrollment) of inhaled corticosteroids, topical steroids, and antihistamines.
Exclusion Criteria
  • * Poorly controlled asthma (Asthma Control Test ≤19).
  • * Self-reported sleep disturbance on 2 or more nights in the past 7 days due to allergic rhinitis.
  • * Use of concomitant medication that causes scratching.
  • * Major medical condition (such as cancer).
  • * Active condition that could affect sleep, such as obstructive sleep apnea, restless leg syndrome, insomnia, narcolepsy, severe sleep disordered breathing, severe depression, COVID-19, or hives (urticaria).
  • * Having applied topical steroids within 7 days of first or second PSG (important for biomarkers assessment).
  • * Use of systemic immunosuppressant within 30 days of first PSG.
  • * Having showered or used moisturizers within 12 hours of first or second PSG.
  • * Unable to communicate in English (some PROMIS questionnaires not available in translation).
  • * Other contraindication to receiving dupilumab (such as history of allergic reaction to dupilumab or any of its components).
  • * Pregnancy.
  • * Clinical blindness (circadian disturbing).
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Location Details

NCT05042258

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Illinois

Lurie Children's Hospital/Northwestern University

Chicago, Illinois, United States, 60611